No clinically significant infections as judged by the treating investigator
Laboratory test values at screening outside of the normal range and judged clinically significant by the investigator
Have evidence of any other significant clinical disorder or laboratory finding that, as judged by the investigator, makes it undesirable for the patient to participate in the study
Clinically significant bleeding event, as judged by investigator, within prior 6 months
Clinically significant hearing impairment, as judged by the Principal Investigator.
EXPANDED ACCESS COHORT: Participants must be experiencing clinical benefit from the 13-506 study drug combination as judged by the treating investigator
Known or suspected history of significant drug abuse as judged by the Investigator
No clinically significant infections as judged by the treating investigator
Concurrent clinically significant infections as determined by the treating Investigator.
Mandatory biopsy on study entry, if the lesion can be biopsied with acceptable clinical risk (as judged by the investigator)
No clinically significant infections as judged by the treating investigator
Patients with rapidly progressing tumors, as judged by the investigator
Clinically active infection (>= grade 2) as judged by the site investigator
No clinically significant infections or any other medical condition(s) that render the subject ineligible for high dose IL-2 therapy as judged by the treating investigator
Prior history of psychiatric disorder or seizure disorders which could be exacerbated by Interleukin-2 as judged by the treating investigator
No clinically significant infections as judged by the treating investigator
Judged by investigator to have progressive disease sufficient to clinically justify standard-of-care radium-223 treatment
Supranormal values judged to be of benign or inconsequential etiology will be acceptable
No clinically significant infections as judged by the treating investigator
Hepatic impairment as judged by clinical investigator or bilirubin > 2
Magnesium >= within institutional normal limits, or =< grade 1 according to NCI-CTCAE version 4.03 if judged clinically not significant by the investigator
Platelet count < 50,000/uL, if these cytopenias are not judged by the investigator to be due to underlying disease (i.e. potentially reversible with anti-neoplastic therapy)
Clinically significant infections as judged by the treating investigator. Subjects must not have been diagnosed with human immunodeficiency virus (HIV) infection, active chronic hepatitis B or C, life-threatening illness unrelated to cancer, or any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with participation in this study. Subjects should be tested for hepatitis B or C or HIV infection during screening only if they are considered by the investigator to be at high risk for these infections.
Patients who are not euthyroid as judged by the investigator.
Patients with clinically significant dermatological disorders, e.g., eczema or psoriasis, as judged by the principal investigator, or any unhealed skin wounds or ulcers
No clinically significant infections as judged by the treating investigator.
History of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant, precluding informed consent, or interfering with compliance or drug intake
Have rapidly progressing disease, as judged by the investigator (e.g., rapid progression through prior treatment[s])
No clinically significant infections as judged by the treating physician.
Patients with psychiatric disability judged by the investigator to be clinically significant so as to preclude informed consent or compliance with drug intake
Patients must agree to have a biopsy at baseline and on treatment if the lesion can be biopsied with acceptable clinical risk (as judged by the investigator)
History of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant, precluding informed consent, or interfering with compliance or oral drug intake
History of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant, precluding informed consent, or interfering with compliance or oral drug intake
History of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant, precluding informed consent, or interfering with compliance or oral drug intake
Clinically relevant cardiovascular abnormalities as judged by the investigator.
Central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant to preclude informed consent or interfere with complying with protocol treatments
Ongoing or clinically significant active infection as judged by the investigator.
Ongoing or clinically significant active infection as judged by the investigator.
History of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant, precluding informed consent, or interfering with compliance or oral drug intake
As judged by the investigator any evidence of severe or uncontrolled systemic disease
No clinically significant infections as judged by the treating investigator.
Concurrent clinically significant infections as determined by the treating investigator.
Aspartate transaminase (AST), alanine transferase (ALT) within institutional limits of normal or judged to be not clinically significant by the investigator
Alkaline phosphatase within institutional limits of normal or judged to be not clinically significant by the investigator
Platelets within institutional limits of normal or judged to be not clinically significant by the investigator
Hemoglobin within institutional limits of normal or judged to be not clinically significant by the investigator
Total bilirubin within institutional limits of normal or judged to be not clinically significant by the investigator
Creatinine within institutional limits of normal or judged to be not clinically significant by the investigator
Evidence of severe pulmonary infections, as judged by the investigator
Provide informed written consent
Provide written informed consent
Provide informed written consent
Provide written informed consent
Subjects must provide written informed consent to participate
Must provide written informed consent.
Provide written informed consent
Provide written informed consent
Willingness to provide informed written consent
Patients who can provide informed consent
Patients must provide written consent
Participant must voluntarily agree to provide written informed consent
Provide written informed consent
Provide informed written consent
Provide informed consent
Provide informed written consent
Provide informed written consent
Provide informed written consent
Provide informed written consent
Provide informed written consent
Provide informed written consent
Patients must provide written informed consent.
Provide written informed consent for the follow up protocol.
Refusal to provide written informed consent
Patients must provide informed consent
Provide written informed consent
Provide written informed consent
Provide written informed consent
Provide written informed consent
Provide informed written consent
Provide written informed consent
Provide informed written consent
Provide written informed consent
Provide informed written consent
Provide informed written consent
Provide written informed consent
Provide written informed consent
Provide informed written consent
Provide informed written consent
Provide informed written consent
Provide written informed consent
Patients must provide written informed consent
Provide written informed consent
Patients must provide written informed consent.
The patient must provide informed consent.
Provide informed written consent
Provide informed written consent
Patients must provide informed written consent
Patients must provide written informed consent
Provide informed written consent
Patients must provide informed written consent
Patients must provide written informed consent
Provide informed written consent
Patients must provide written informed consent
Provide written informed consent for the trial
Provide informed written consent
Must provide written informed consent
Participant must provide informed consent
Patients must provide written informed consent
Provide informed written consent
For Phase I and II: Patients must provide written informed consent.
Subjects who provide written informed consent to participate in the study
Willingness to provide written informed consent for the study.
Provide written informed consent prior to any study related procedure.
Provide informed written consent
Provide written informed consent to participate on the study
Patients must provide written consent
Provide written informed consent
Provide written informed consent
Provide written informed consent
Participant unwilling to provide written informed consent
Patients must provide written informed consent.
Provide written informed consent
Can provide informed consent
Provide written informed consent
Provide written informed consent
Provide informed written consent
Provide informed written consent
Provide informed written consent
Patients must provide informed written consent
Provide written informed consent
Provide informed written consent
Willingness to provide informed consent
Provide written informed consent
Provide written informed consent
Patients must provide verbal and written informed consent to participate in the study
Patients must provide written informed consent.
Willingness to provide written informed consent for the study.
Provide informed written consent
Participant must voluntarily agree to provide written informed consent.
Patients must provide written informed consent
Patients must provide written informed consent
Provide written informed consent
Provide written informed consent
Provide informed written consent
Provide informed written consent
Provide written informed consent
Provide informed written consent
Provide informed written consent
Provide informed written consent
Provide informed written consent
Provide informed written consent
Patients must provide informed consent
Patients must provide verbal and written informed consent to participate in the study
Patients must provide written informed consent prior to any registration on study
Provide informed written consent
Provide written informed consent
Provide informed written consent
Provide written informed consent (Screen 1 and Screen 2)
Provide informed written consent
Provide informed written consent
Patients must provide informed written consent
Provide informed written consent
Patients who provide written informed consent for participation in this trial
Provide informed written consent
Provide written informed consent
Provide informed consent
Provide written informed consent
Patients must provide written informed consent
Provide informed written consent
Patients must provide informed consent
Provide informed written consent
Willingness to provide written informed consent for the study.
Provide written informed consent.
Provide informed written consent
Patients must provide written informed consent.
Provide informed written consent
Provide written informed consent
Provide informed written consent
Provide informed written consent
Provide informed written consent
Provide written informed consent
Provide informed written consent
Patients must provide written informed consent
Provide informed written consent
Provide informed written consent
Provide written informed consent
Provide informed written consent
Both must provide informed consent
Provide written informed consent
Must provide written informed consent
Provide written informed consent
Provide written informed consent
Provide written informed consent prior to screening
Can provide informed consent
Provide informed written consent
Provide informed written consent
Provide informed written consent
Patients must provide written informed consent to participate in the study
Provide informed written consent
Provide informed consent
Patients can provide informed consent
Willingness to provide written informed consent
Provide written informed consent.
Provide written informed consent for the study
Cannot provide written informed consent
Cannot provide written informed consent
Provide informed written consent if >= 18 years; if < 18 years, provide informed written assent and parent or legal guardian provide informed written consent
Provide written informed consent
Patients must provide written informed consent
Cannot provide written informed consent
Provide informed written consent
Patients must provide informed written consent
Patients must provide written informed consent
Cannot provide written informed consent
Provide informed written consent
Can provide informed consent
Participants must voluntarily agree to provide written informed consent.
Have participated, within the last 28 days in a clinical trial involving an investigational product or are currently enrolled in a clinical trial involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.
Have received treatment within 21 days of the initial dose of olaratumab with an investigational product or non-approved use of a drug or device or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
Are currently enrolled in a clinical trial involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.
Currently enrolled in, or discontinued within the last 14 days from a clinical trial involving an investigational product or non-approved use of a drug, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
Are currently receiving an investigational drug in a clinical trial or participating in any other type of medical research judged not to be scientifically or medically compatible with this study
Are currently receiving an investigational drug in a clinical trial or participating in any other type of medical research judged not to be scientifically or medically compatible with this study
Are currently enrolled in, or discontinued within the last 28 days from a clinical trial involving an investigational drug or device or not approved use of a drug or device (other than the study drug used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
Have received treatment within 28 days of the initial dose of study drug with an investigational product or non-approved use of a drug or device (other than the study drug/device used in this study) or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational drug or device or off-label use of a drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
Enrolled in a clinical trial involving an investigational product or nonapproved use of a drug or in medical research judged not to be scientifically or medically compatible with this study.
Have received treatment within 28 days prior to the initial dose of study drug with an investigational product or non-approved use of a drug or device (other than the study drug/device used in this study) for non-cancer indications or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
Are enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study within 28 days of the initial dose of study drug.
Willingness and ability to provide written informed consent and to comply with the study protocol as judged by the investigator
Ability to provide written informed consent
Willingness and ability to provide written informed consent and to comply with the study protocol as judged by the investigator
Ability to provide written informed consent
Ability to provide written informed consent
Ability to give written informed consent
Ability to provide written informed consent.
Ability to provide written informed consent for the protocol
Ability to provide written informed consent
Ability to provide written informed consent
Ability to provide written informed consent
Ability to provide written informed consent
Willingness and ability to provide written informed consent and to comply with the study protocol as judged by the investigator
Ability to provide written informed consent.
Ability to provide written informed consent
Ability to provide written informed consent
Ability to give written informed consent
Ability to provide written, informed consent
Ability to provide written informed consent
Ability to provide written informed consent
Ability to provide written informed consent
Ability to provide written informed consent
ARM A: Ability to provide informed written consent
ARM B: Ability to provide informed written consent
Ability to provide written informed consent
Ability to give written informed consent
Ability to provide written informed consent
Willingness and ability to provide written informed consent and to comply with the study protocol as judged by the investigator
Ability to provide informed written consent
Ability to provide written informed consent and comply with study requirements
Ability to provide informed written consent
Ability to provide written informed consent
Ability and willingness to provide written informed consent
Ability and willingness to provide written informed consent
Ability to provide informed written consent
Ability to provide written informed consent
Ability to provide written informed consent
Patient must have the ability to give written informed consent
Ability to provide written informed consent. Evidence of a personally signed informed consent.
Ability to provide informed written consent
Ability to provide written informed consent
Ability to give written informed consent.
Ability to provide written informed consent
Have ability to provide full written consent
Ability to provide informed written consent
Have the ability to give written informed consent
Ability to provide informed written consent
Ability to provide informed written consent
Ability to provide informed written consent
Ability to provide informed written consent
Ability to provide written informed consent
Ability to provide informed written consent
Ability to read and provide written informed consent
Ability to provide written informed consent
Ability to provide written informed consent in accordance with institutional policies
Ability to provide written informed consent
Ability to provide written, informed consent.
Ability and willingness to provide written informed consent
